Tag Archives: health innovation

The Population Health Colloquium: Social Determinants of Health, Precision Medicine and the Triple Aim

By Fred Goldstein, MS and Gregg Masters, MPH*

The field of population health continues to grow and create new areas of exploration and integration. Population health practitioners are called upon to play a central role as health systems, health plans or healthcare organizations work to implement their strategies designed to improve health care quality, access, outcomes and cost while weaning the US Healthcare system away from its fee-for-service reimbursement paradigm.

From the emerging recognition that Precision Medicine is not antithetical to population health, to the development of unique approaches to address the social determinants of health, it’s an exciting time.

This year’s agenda for the Population Health Colloquium reflects the dynamic nature of the field, featuring leading healthcare experts from academia, healthcare systems, health plans, data and analytics companies, population health companies, regulators, innovators and entrepreneurs. To add to the excitement, the $100,000 Hearst Health Prize will be awarded to one of three deserving finalists: the University of Arkansas Arkansas SAVES program; the Mental Health Outreach for Mothers (MOMS) Program; and the Sharp Transitions Program.

A range of value-based care and alternative payment models are being implemented across the U.S. healthcare landscape, and will be covered in depth at the Colloquium with presentations on ‘Are Alternative Payment Models Working?’ presented by Lawton R. Burns, PhD, MBA, Director of the Wharton Center for Healthcare Management and Economics and the James Joo-Jin Kim Professor of Health Care Management, Wharton School, University of Pennsylvania, and François de Brantes, MBA, Senior Vice President of Commercial Business Development, Remedy Partners. There will also be a number of ‘mini-summits‘ addressing value-based care and alternative payment models in different contexts and settings (orthopedic bundle, collaborative care, chronic conditions, patient engagement, and elder care).

The move to alternative sites of care will be covered in ‘Evolving Care Outside the Hospital to Meet Consumers Where They Are’, presented by Niki Buchanan, MA, PHM, General Manager, Philips PHM, and Shauna Coyne, Director of Innovations, New York-Presbyterian Hospital.

A Special Dinner Program (Tuesday, March 19), download brochure here.

Cells Are the New Cure: Advances in Precision Medicine‘ will focus on innovations, science, technology and medicine and explore the advances in precision medicine that are providing pathways to cures using human cells. The Panel will include, Richard M. Cohen Journalist, News Producer, “Dr. Max” Gomez, PhD, an Emmy-Award Winning Medical Correspondent, Robin L. Smith, MD, MBA, President and Chairman, Cura Foundation, and Meredith Vieira, Emmy Award-winning TV Journalist; Host, Executive Producer and Anchor.  Attendees at this event will each receive a copy of ‘Cells are the New Cure’ by Robin Smith, MD, MBA and “Dr. Max” Gomez, PhD and ‘Chasing Hope’ by Richard M. Cohen.

Join us on PopHealth Week, Wednesday, March 6th, as we chat with co-authors Max Gomez, PhD, and Robin L. Smith, MD, MBA to preview the principal message featured in their book including implications for population health management.

A major focus of the final day will be looking at the healthcare system itself, discussing what’s wrong and how we (including healthcare consumers) can fix it. Presentations will be given by Robert Pearl, MD, Contributor, Forbes; Professor, Stanford University School of Medicine, author of ‘Mistreated: Why We Think We’re Getting Good Health Care — and Why We’re Usually Wrong, Elisabeth Rosenthal, MD, Editor-in-Chief, Kaiser Health News, author of ‘An American Sickness: How Healthcare Became Big Business and How You Can Take It Back and Archelle Georgiou, MD, President, Georgiou Consulting; Author and Consumer Advocate, author of ‘Healthcare Choices: 5 Steps to Getting the Medical Care You Want and Need.

To conclude the Colloquium, the ever popular Health Leaders Panel will be moderated by Dr. Nash. This year’s line-up includes Mandy Mangat, MD, MPH, Chief Medical Officer, Navvis Healthcare; David Nace, MD, Chief Medical Officer, Innovaccer; Rita Numerof, PhD, President, Numerof & Associates, Inc.; and Gary A. Puckrein, PhD, President and Chief Executive Officer of the National Minority Quality Forum.

And that’s only a peek at some of the timely presentations, panels and mini-summits at this year’s Colloquium. If you haven’t registered yet, (more information here), there’s still time to block your schedule, secure your travel arrangements and come to the best Population Health Conference of the year,  March 18-20th at the Loews Philadelphia Hotel, in the City of Brotherly Love.

Still on the fence?, check out this invitation to the Colloquium via David B. Nash, MD, MBA, Dean, Jefferson College of Population Health, and our last chat with Dr. Nash, inAccelerating toward “Value Based Care”…or, “No Outcome, No Income”.’

We hope to see you there!

==##==

* Post sponsored by the Jefferson College of Population Health

@HIMSS 2019: @Accenture Global Health Practice Head @DrKavehSafavi Highights Consumer Health Survey Results

By Gregg A. Masters, MPH and Frederic S. Goldstein, MS

In what has become a HIMSS (Health Information Management Systems Society) tradition Health Innovation Media co-host Fred Goldstein sat with Kaveh Safavi, MD, MBA, Senior Managing Director and Head of Global Health Practice for Accenture to source the latest trends, developments and sentiment on the future of healthcare from the ‘consumer‘ point of view.

The growing impact of technology to empower and democratize healthcare can not be denied. This is both a warning and an opportunity for legacy healthcare operators to retool their business models, footprints, culture and the strategic positioning of assets (both virtual and ‘brick and sticks’) to serve an increasingly motivated, and to a certain extent dis-satisfied healthcare consumer.

Bottom line? Active participation, pricing transparency and shared decision making – beyond mere ad copy – is no longer an option. Watch this space!

Noteworthy interview points include:

½ of respondents in US use non-traditional healthcare services and ¼ use digital nontraditional means to access healthcare

Rapid growth in people wanting to use a digital channel as an alternative to the current healthcare system

Sentiment shift driven by what’s been happening outside healthcare

Dis-satisfaction with the healthcare system from the younger generation – access and location, will probably not change as they age…

Artificial Intelligence (AI) presents a means to generate efficiencies in the system, see AI And Healthcare: A Giant Opportunity

In this interview Dr. Safavi highlights key findings of Accenture’s 2019 Digital Health Consumer Survey.

The report’s executive summary notes:

Healthcare consumers today are changing, and their expectations for convenience, affordability and quality are redefining how they engage at each stage of care.

Younger consumers are not satisfied with healthcare’s status quo and consumers of all generations are more willing to try non-traditional services.

Non-traditional healthcare, such as virtual care and retail walk-in clinics, is gaining in popularity and use.

There is lots to digest in Accenture’s latest consumer sentiment survey. Be sure to check out the video interview, download the survey and read the Forbes piece which validates much of Dr. Safavi’s narrative.

Enjoy!

Accelerating toward “Value Based Care”…or, “No Outcome, No Income”

By Gregg Masters, MPH and Fred Goldstein, MS

The concept of ‘managed healthcare’ has been part of the health policy lexicon in one way or another for decades, and has been variably embraced and scorned by different stakeholders.  Now that costs have reached unsustainable highs and life expectancy for Americans is on the decline, we’ve finally begun exploring ways to move from a ‘sick care model’ to one that values the health of the individual and the community.

Individuals point to the legacy U.S. fee-for-service payment model as either the inflationary culprit of a cost prohibitive, often inaccessible healthcare delivery system with wide variations in both quality and outcomes, or conversely, as the ‘strong medicine’ our challenged ‘health system’ requires. U.S. healthcare per capita spending is at a 2-5x that of its international peers (developed nations in the OECD) since it’s fueled by a set of incentives that encourage healthcare providers to ‘do more, to earn more’.

Our industry remains challenged to transform its care delivery model to enable the system to consistently deliver high quality care at reasonable price points both the end user (patient or consumer) or third party payer deem to be ‘fair value’ or reasonable.

Robust conversations in board rooms of major healthcare organizations have focused on the impact of the social determinants of health – non-clinical concerns (food and housing insecurity, poverty, education and employment) – on health status, have leaders beginning to direct their focus outward in an effort to understand how health care delivery must change to meet these critical needs. 

It’s generally acknowledged that when payment is ‘episodic’ in nature (fee-for-services) we incentivize a sick care model that merely treats symptoms without impacting overall health. When we examine health from a population-level perspective, we are able to address health maintenance or promotion at the individual or community level, by putting a spotlight on the causes of the underlying presenting ‘dis-ease’.

Both Government and the private sector are actively looking to transfer risk via a range of payment models from capitation to bundles, to all-inclusive population-based payments. However, their uptake has been slow, spotty and has met with variable degrees of success. Yet, all are organically converging under a ‘population health’ perspective or frame of mind.

Conceptually, a ‘population health’ approach makes enormous sense.  Because it typically involves connecting with stakeholders and organizations outside the healthcare delivery system, successful implementation often presents with significant challenges. The ‘how to’ is often disguised in myriad choices not easy to discern, differentially evaluate, and fund.

By all appearances, the move away from fee-for-service medicine to value based healthcare is accelerating.  Underlying this change is the not insignificant question of how one successfully completes the transition to the new paradigm while maintaining care quality and financial margins.

Some have downplayed the impact of population health…or positioned it in opposition to another high priority theme for healthcare leaders, i.e., precision medicine.  Yet, it is, in fact, the framework for success. Understanding the specific characteristics of the target population is the open window into the risk, outcomes and costs associated with the group, and the best way to truly measure one’s impact over time. Did the health of the group of persons we served improve overall?

There is good news for those who view precision medicine and targeting individuals as the ideal approach; in fact, the two actually can co-exist. Assessment and stratification, resulting in an intervention(s) to the individual are key characteristics of both precision medicine and population health frameworks. The introduction of genomics, proteomics and other more “individualized” assessment measures allows for a more precise determination of risk, stratification and selection of the appropriate intervention(s). 

None of this is easy, but it is necessary if we are to improve the health of our nation’s citizens in a financially responsible way. Social determinants of health play an oversized role in health status, and in order to address them effectively, we must undertake new approaches and thinking, working in broader coalitions and collaborative community partnerships.

Enter the Population Health Colloquium

Jefferson College of Population Health opened a decade ago, under the direction and guidance of its Founding Dean, David B. Nash, MD, MBA, as the first institution dedicated to the study of population health. Since 2008, it has been adding value via research, empirically demonstrated best practices and stewarding the training of the practitioners equipped to connect health with healthcare delivery.

In its 19th iteration, the Colloquium is an immersive experience that brings together thought leaders, innovators and entrepreneurs across the care continuum, including health policy wonks and regulators, to network and learn from one another.

Dr. Nash extends his invitation to the community in the video below:

This Wednesday, February 6th at on PopHealth Week, Dr. Nash chats with Niki Buchanan, Population Health Management Lead at Philips Wellcentive.

For more information on the 19th Population Health Colloquium including keynote faculty and the program agenda, including the Hearst Health Prize, click here.

See you in Philly!

LIVE From @HIMSS 2019 #HIMSS19

by Gregg A. Masters, MPH & Nick van Terheyden MD

Ten plus years in to what some consider ‘top down’ (vs. ‘bottoms up’) artificial stimulation by HITECH/ARRA of a vendor/supplier ecosystem offering a range of ‘not ready for prime time‘ electronic health or medical records, we’re still searching for remedies to chronic user concerns and well documented interoperability issues, see: ‘Electronic Health Record (EHR) Safety and Usability. See What We Mean‘ published by Medstar Health National Center for Human Factors in Healthcare.

Our ‘pluralistic‘ American healthcare ‘non’-system is unique on a number of levels not the least of which is the 2-4x spend multiple when contrasted to other developed nations reporting to the Organization for Economic Cooperation and Development (OECD).

Yet, the U.S. historically driven by it’s once ‘good ole yankee ingenuity’ (now increasingly of the imported/immigrant driven variety) has deep roots and legitimate claims to the title of the center of gravity of the innovation impulse.

To many, ‘American Exceptional-ism‘ means we can reliably innovate ourselves out of just about any social, economic or other national dilemma from climate change to fulfilling the promise of the triple aim (better experience of care, improved outcomes at lower per capita costs).

Enter The Voice Play: Will Voice Dominate HIMSS?

From desktops to keywords to now voice commands to remote or networked devices, smart phones or tethered i-Watches whether ingested by machine driven deep learning algorithms developed by Apple for SIRI, or ‘Ok Google’ for search or even the growing home or office ‘Alexa’ commands intent to make our lives easier, we’re well into the ‘IoT’ era where voice may just be the enabling equivalent of ‘digital capital’.

Health Innovation Media has been following and reporting from HIMSS since 2010. In 2013 we launched the first guerrilla new media operation wirelessly streaming live content from the Exhibit Hall to one-on-one interviews with top talent from our ‘pop-up studio‘, see: ‘5 Days in March: A Tale of Independent Media Passion, Determination and Agility‘.

This year thanks to Nuance, the leader in ‘conversational AI‘ for health, this will be our fourth year in row co-locating our pop-up studio on the floor in the HIMSS Exhibition Hall.

LIVE From HIMSS 2019

We’re broadcasting ‘LIVE From @HIMSS 2019‘ two hours per day, beginning Tuesday, February 12th from 11AM – 1PM and Wednesday, February 13th, from 1PM – 3PM. All times are Eastern.

The schedule of include:

Our studio will be hosted in the Nuance Communications booth #3345. The area floor plan is pasted below:

HIMSS Exhibition Floor Plan


Context for Nuance’s pivot to an ‘all in on conversational AI‘ in health can be found in recent presentation by Mark Benjamin, CEO to the JP Morgan Healthcare Conference (NOTE: this link has time limited access and though free, registration may be required) in San Francisco and likely to be affirmed with management’s discussion of operating results during Nuance’s Q1 2019 results conference call, February 7th, 2019 5:00 PM ET, register here.

Meanwhile, Nuance announced their partnership with MEDITECH focusing on new AI-Powered Virtual Assistants for Healthcare building on years of experience to integrate their new virtual assistant into the clinician workflow to facilitate the clinicians patient interaction removing the data access drudgery and freeing the clinicians to focus on the patient.

Additionally, Nuance has issued the following:

First Quarter 2019 Results

Nuance Brings Virtual Assistant Technology to 300,000 Dragon Medical One Cloud Users

On LIVE From HIMSS 2019 we’ll be discussing these innovations and their application at the clinical work face with clinicians, users, experts and patients exploring the new world using voice to demystify technology and easing the learning and technical challenges long associated with electronic health records.

So will voice be the game changer in healthcare that brings the vision of the triple aim one step closer to the industry’s collective grasp? We think a pretty strong argument can be made here.

==##==



HIMSS 2019: A Call For Champions Of Health To Unite

by Gregg A. Masters, MPH

HIMSS‘ (Health Information Management Systems Society) the undeniably trophy event for the health information technology sector ranging from disruptive digital health startups to enterprise wide solutions providers (both legacy and cloud based) for health systems, health plans, IDNs, ACOs, patient centered medical homes and more is again convening in Orlando from February 11th – 15th, 2019 at the Orange County Convention Center.

This year Health Innovation Media the leader in former C-suite hands on operators with domain specific subject matter expertise in engaging thought leaders, entrepreneurs and health policy wonks in their craft is for the fourth year in a row co-locating it’s signature ‘pinksocks pop-up studio‘ on site with Nuance, Inc., including Nuance Health.

Our ‘LIVE From HIMSS 2019‘ broadcast with co-hosts Nick Van Terheyden, MD and Fred Goldstein, MS, schedule including guests will be published shortly. Meanwhile, enjoy this look back and preview of HIMSS 2019:

What I Didn’t See at @JPMorgan Healthcare Conference #JPM19

by Gregg A. Masters, MPH

For many reasons the JP Morgan Healthcare Conference seems to serve as the launching pad for what will trend for the balance of the year 2019. From pharma, to biotech, health system, integrated delivery networks, personalized or precision medicine or medical device innovation the potpourri and range of presenting companies provide definite insights beyond the hedged ‘forward looking statements’ reporting in advance of annual or quarterly SEC filings.

Often buried in formal mostly arcane disclosure statements are ‘strategic kernels‘ of what to expect in management’s discussion or operating results including material competitive concerns, any known or expected enabling ‘IP’ or other secret sauce tailwinds or conversely oppositional headwinds of whatever form.

As opined often and elsewhere in years past, see: ‘If Its January, It’s JP Morgan Healthcare Conference‘, a rich stream of those insights could be sourced from the ‘non-proft track‘ where major health systems – arguably the ‘innovation uptake gatekeepers’ – discuss their strategies including the range of joint venture or affiliate companies to work around their typical tax exempt or non-profit status.

Unfortunately, JP Morgan has chosen NOT to stream these vital sessions.

The other ‘conspicuous absence‘ with the exception of GW Pharmaceuticals was the emerging cannabis sector given its growing body of evidence as a viable therapeutic alternative to many current approved medicines, from pain management to the treatment of epilepsy. Cannabis was legalized ‘recreationally‘ at the federal level in Canada in October of this year, joining Uruguay.

In the United States the repeal of the federal prohibition is inevitable in the opinion of this author. For context see: All the places in the world you can (legally) get high on 4/20. The national ‘heat map’ below provides the ‘recreational’ vs. ‘medical‘ marijuana picture by state which continues to build out often in some surprising places. It’s not if, but when.

Make no mistake, medical is the foot in the door that states will not be able to resist given the allure of potential tax receipts in state treasuries or the growing body of evidence of its medical upside.

The one cannabis company I found on the agenda of reporting companies at JP Morgan Healthcare Conference was GW Pharmaceuticals, PLC:

the global leader in developing cannabinoid-based medicines

courtesy of Justin Gover its Chief Executive Officer. The link to the session is here, these are time limited streams as JP Morgan pulls the plug on the content some 60-90 days out. Be sure and listen Glover’s pitch and follow along via the deck supplied.

NOTE: While access is free via JP Morgan Healthcare Conference portal, registration is required for the links supplied in this post. You can register here.

There is so much more to come from the cannabis sector as both consumer product companies (see What Constellation Brands’ Massive Investment In Canopy Growth Corp. Means For Both Companies) and pharma giants scour the landscape to find suitable entry points (both acquisitions and mergers) to participate in the inevitable rise of the cannabis sector – both ‘high margin‘ medical and the massive upside of infusion products from beverages to lotions to you fill in the blank.

If your interest is piqued at all here, one source of tracking the public cannabis sector is via New Cannabis Ventures published by Houston based Alan Brochstein, CFA.

As always, I invite your comments including alternative points of view.

Best!

#JPM19 Best Bets

by Gregg A. Masters, MPH

Two bellwether companies reported on their operating results including industry headwinds and tailwinds given the instability of macro industry pivots from a ‘do more to earn more‘ (fee-for-services) production mindset to ‘loose‘ (where any ‘ Rorschach‘ projection will do) notions of what a ‘value based‘ healthcare, tech or systemic approach looks, feels and walks like.

In other words, in this admittedly murky transformational environment, the challenge of positioning a viable consolidated enterprise (for the CVS Health & Aetna combination as well as others pondering the implications of the volume to value journey) the seminal question remains: is the strategy pivot about grafting innovation (via acquisition or internal re-positioning) on top of an otherwise legacy driven culture and operational chassis, or is it a complete re-tooling of the enterprise?

Might focused tweaks work, or is a fundamental re-structuring of the business model and operating footprint the strategic imperative? And if the latter, what does that look like and is there a national replicable footprint?

I found the presentation by Larry Merlo, President & CEO, CVS Health aka the ‘tail that wagged the dog‘ at legacy health insurer Aetna (though Mark Bertolini would no doubt beg to differ with my legacy label – think 90’s U.S. Healthcare debacle and subsequent entry and exits from ambitions efforts at new business development at Healthagen) to be sensible and promising. As a strategist at many misfires (and some managed care successes) at major for-profit, tax exempt, academic and regional referral center hospital or health system pivots I was skeptical that this modestly ‘atypical player‘ marriage made sense and could be pulled off in a sustainable way.

See what you think… reading the tea leaves from diversified (via acquisition or internal baking) and often potentially conflicted ‘legacy‘ vs. ‘new market‘ opportunity plays can be a challenging set of incentives to navigate, manage and scale in a healthcare economy pivoting from volume-to-value.

You can access both via the JP Morgan webcast portal for a limited time here. This is a free service but does require your registration. Search the ‘sessions’ tab for the respective webcast. Some of the reporting companies’ supply their decks for reference as well.

The other report I found of strategic value from a trophy name plate operator in the midst of it’s own pivot, in the lab space was provided via industry leader and consolidator LabCorp courtesy of David King its Chairman & CEO.

Your thoughts and comments are welcome.

Day One #JPM19

by Gregg A. Masters, MPH

The must be a part of healthcare investor gathering launches today in San Francisco – perhaps for the last time.

Fortunately, JP Morgan continues its tradition of inviting access and engagement in the content streamed by participating companies. In order to access the program agenda, list of participating companies, profiles, supporting decks and scheduled webcasts you need to register and agree to the terms of service stipulated by the underwriting host and principals from JP Morgan.

The portal for registration is accessible here.

The Monday morning line-up kicks off with many bellwether pharma and biotech performers including Celgene’s  pending acquisition by Bristol Meyers Squibb in the convergent pharma, life sciences and biotech sectors, as well the year end results from Medicaid managed care market leader Centene (including the combined operating performance of California innovator in the HMO space, HealthNet).

There is so much to follow to gain insights on the performance of operators in the payor, provider and supplier, including medical device sectors.

Do not miss this time limited availability of material insights into the complex ecosystem of the U.S. healthcare economy.

37th JP Morgan Healthcare Investor Conference

by Gregg A. Masters, MPH

When William Hambrecht and George Quist founded Hambrecht & Quist (H&Q) in 1968, the ’boutique’ firm launched as an investment bank based in San Francisco, California notably focusing on the then emerging yet rather nascent technology and Internet sectors.

Clearly, Bill and George were a prescient duo as H&Q was:

“an early player in the technology sector, underwriting initial public offerings (IPOs) for Apple Computer, Genentech, and Adobe Systems in the 1980s. In the 1990s, H&Q also backed the IPOs of Netscape, MP3.com, and Amazon.com.”

Some 36 annual conferences later, and now squarely in the hands of perhaps the prototypical trophy U.S. investment bank, JP Morgan, H&Q’s legacy ‘healthcare investor‘ commitment has morphed into a life sciences, biotech, pharma and healthcare innovation ‘mega‘ event that is both going strong and has seeded several derivative strains of related gatherings from the DOCSF to the StartUp Health Festival, the BioTech Showcase and many other ecosystem stakeholders footprints including broker, management consulting, accounting and law firm sponsored events, i.e., the combined Deloitte, E & Y & McDermott Law gathering.

You can access both via the JP Morgan webcast portal for a limited time here. This is a free service but does require your registration. Search the ‘sessions’ tab for the respective webcast. Some of the reporting companies’ supply their decks for reference as well.

According to JP Morgan Healthcare website, and implied below via ‘while it is still at the Westin‘ – this is the last year San Francisco will host this must attend event – the firm scales the gathering as follows:

“Today, while it is still at the Westin St. Francis in San Francisco, the annual J.P. Morgan Healthcare Conference brings thousands of investors from around the world together. The hundreds of companies presenting run the gamut, from start-ups to those with more than $300 billion in market cap, and encompass the entire global healthcare landscape, including pharmaceutical firms, healthcare service providers, profit and not-for-profits, and medical device companies.”

JP Morgan Guides

This week of somewhat ‘frenetic‘ activity can be tough to schedule and navigate. Some of the best guides we’ve found are provided by BIO via their ‘One-on-One Partnering™ @ JPM, Rock Health, Big3BioSF, and relative ‘newcomer‘ and registrar dot.health.

For the ultimate private event, reception and party calendar, c/o BIO and MacDougall Biomedical Communications see: ‘Private Events around the JP Morgan Healthcare Conference.’

Tracking the conversation

For the 5th out of the last 6 years, Health Innovation Media has registered the #JPM19 ‘un-official’ hashtag courtesy of the ‘go-to‘ health hashtags project sponsored by Symplur. The digital dashboard is accessible here.

You can also pull time limited transcripts of tweets and select analytics demonstrating the reach, engagement and ‘social capital‘ of participants in the conversational stream.

Follow tweets via #JPM19 and consider following me via @2healthguru.

WISH 2018 The World Innovation Summit for Health

by Gregg A.  Masters, MPH

It’s just 15 hours +/- 25 minutes or so by direct flight (I flew on Qatar Airways – amazing food and exceptional service especially when compared to U.S. domestic carriers) from Los Angeles International Airport to Doha, Qatar (pronounced kah-tar).

Once the internal bio-clock adjusts to an initial dis-orientation (a flip) of a + 11 hour time zone shift, one is welcomed to Doha by a culture steeped in a tradition of courtesy and service, amidst a towering series of skyscrapers clustered in Doha City.

My time in Doha was by invitation to attend and report on certain events planned at the World Innovation Summit for Health (WISH) Summit running Tuesday and Wednesday, November 13th and 14th, 2018.

Live Stream

There will be a live stream. WISH intends to stream select content below:

Follow tweets via #WISH2018 or #WISHQatar2018. The former digital dashboard is here.

Details on WISH note:

Around 2000 healthcare experts, innovators, entrepreneurs, policymakers, and ministers from over 100 countries will gather in Doha, Qatar, on November 13-14 as ONE community to collaboratively work to achieve ONE goal: a healthier world. 

WISH 2018 reflects the vision of the World Innovation Summit for Health, which is to build a healthier world through global collaboration. At WISH 2018 delegates will have the opportunity to openly share, collaborate and innovate in order to advance innovation in healthcare. 

Join us on November 13-14 to explore some of the world’s most exciting innovations, to delve into new evidence-based ideas and practices, to forge new connections and to contribute to the development of fresh insights that will help shape health policy around the world for years to come. 

This year’s program includes panel discussions on a wide range of topics pertaining to some of the world’s most pressing healthcare issues, such as eye health, precision medicine and anti-microbial resistance. You will also have an opportunity to explore the WISH Innovation Hub and meet with global health experts and innovators. To check out this year’s program, click here.

Access all information including past WISH sessions, here.

The WISH agenda is organized into the 9 themes below:

WISH is featuring a series of start-up companies via their showcase, including:

  • WATIF Health Portal: a chronic disease decision management portal.
  • The VeinTrain Vein Flatpack Training System: a ‘flat-pack’ tool that enables practical simulation core training.
  • TrustCircle: addresses one of the greatest healthcare challenges our society faces today – the decline in emotional well-being.
  • Tilapia skin burn bandage: a frugal and effective option to treat patients with second- and third-degree burns.
  • Aravind Eye Care System: providing eye care to remotely-based populations via telemedicine-enabled Vision Centers to better meet health needs of remote populations.
  • TechTeb: an Uber-like mobile app for booking healthcare in-house visits according to geographical location.
  • SyntheSci: provides instant data location and intelligent integration of scientific research findings. It finds evidence-informed answers at the click of a mouse.
  • SubQ Assist: a task-shifting medical device that simplifies the administration of long-acting contraceptive implants.
  • Healthy.io: the first company to turn the smartphone camera into a regulatory approved clinical device.
  • SeeDo: technology offers an early intervention for deaf children from 1-7 years of age that brings about remarkable change in their lives.
  • Proximie: an innovative reality platform allowing doctors to virtually transport themselves into any clinical setting to collaborate, train, teach and support other surgeons and medical experts.
  • Pristina Dueta™: the first wireless remote-control device that allows patients to control their own breast compression during a mammogram with the guidance of a technician.
  • One Three Biotech: an artificial intelligence-driven platform that combines over 25 different types of biological, chemical and clinical data to quickly and accurately identify new potential drugs and predict their mechanisms.
  • On call: antibiotics (OcA): the first electronic health game for computer and mobile devices dedicated to improving antimicrobial prescribing behaviors in hospital prescribers.
  • One Medical: a tech-enabled primary care delivery system with over 70 offices across 8 markets in the United States.
  • HydrUStent: a biodegradable, antibacterial and tailor-made stent with patent protection. HydrUStent reduces the risk of bacterial infection, while also decreasing the number of surgical procedures by half and cutting treatment cost by 60%.
  • Himachal Tele Emergency Project: In partnership with the local Department of Health and Family Welfare, Apollo Hospital’s Himachal Tele-Emergency Project provides affordable, quality urgent care services to communities in isolated regions of hostile climate.
  • Electronic-Urban Primary Health Centers (eUPHC): provides comprehensive healthcare and a spectrum of specialist services, such as cardiology, orthopedics, endocrinology and medicine through telemedicine systems in India.
  • Crispvision eye test kits: affordable and accessible sight-saving kits used to detect eye defects, correct farsightedness, and monitor debilitating eye diseases, such as cataract, onchocerciasis and trachoma.
  • Coordinate My Care (CMC): a clinical service underpinned by a digital solution. It provides an advance care planning process that empowers clinicians to create quality urgent care plans, transforming care for all vulnerable patients, and delivering improved quality at a reduced cost.

Twitter

Do follow companies’ participating in the WISH Showcase via twitter handles: @watifhealth @AravindEye @techteb #SubQAssist @_UMGHDI @Healthyio1 @SeeDorobot @ProximieAR @GEHealthcare @OneThreeBiotech #Oncallantibiotics @imperialcollege @onemedical #HydrUstent @Abarros27 @ApolloTeleMed @eunaudoha @trustcircle  

More information on WISH can be found in an impressive forum faculty and chair line-up and the program schedule.